title: Angiotensin (1-7) reduces intraocular pressure in the normotensive rabbit eye.
abstract: OBJECTIVE
  In the present study the effects of exogenous angiotensin II and its breakdown metabolite angiotensin (1-7) on the intraocular pressure (IOP) and on aqueous humor dynamics in normotensive rabbit eye were evaluated.
  
  
  METHODS
  Male New Zealand White rabbits with normal IOP were used for intravitreous and topical administration of the test compounds. IOP was measured in conscious rabbits by pneumatonometer after topical anesthesia. Outflow measurements were made with a two-level constant pressure method in anesthetized animals.
  
  
  RESULTS
  Angiotensin (1-7) administered intravitreously reduced IOP within 1 to 5 hours (P < 0.05). This effect was abolished by the selective angiotensin (1-7) antagonist A-779, and partially by the selective angiotensin II type 2 receptor antagonist PD123319. When olmesartan, an angiotensin II type 1 receptor blocker, was administered simultaneously with angiotensin (1-7), no antagonism was seen. Intravitreous administration of CGP42112 A, an angiotensin II type 2 receptor agonist, and angiotensin II did not significantly influence IOP, nor did topical administration of these compounds alter IOP. Angiotensin II significantly reduced outflow facility (P < 0.01) dose dependently, whereas angiotensin (1-7) had no effect.
  
  
  CONCLUSIONS
  Angiotensin (1-7) is a biologically active vasodilatory and antiproliferative heptapeptide, and its vascular effects counteract those of angiotensin II. It reduces intraocular pressure possibly by a selective Mas receptor, without changing aqueous humor outflow facility in the normotensive rabbit eye.
authors.affiliation: Institute of Biomedicine, Pharmacology, University of Helsinki, Finland. anu.vaajanen@fimnet.fi
authors.forename: Anu
authors.initials: A
authors.lastname: Vaajanen
authors.forename: Heikki
authors.initials: H
authors.lastname: Vapaatalo
authors.forename: Hannu
authors.initials: H
authors.lastname: Kautiainen
authors.forename: Olli
authors.initials: O
authors.lastname: Oksala
mesh_terms: D000287:Administration, Topical; D000803:Angiotensin I / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D000804:Angiotensin II / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors / Q000494:pharmacology; D057912:Angiotensin II Type 2 Receptor Blockers; D000818:Animals; D001082:Aqueous Humor / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D007093:Imidazoles / Q000494:pharmacology; D007267:Injections; D007429:Intraocular Pressure / Q000187:drug effects*; D008297:Male; D009842:Oligopeptides / Q000494:pharmacology; D010446:Peptide Fragments / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D011725:Pyridines / Q000494:pharmacology; D011817:Rabbits; D044139:Receptor, Angiotensin, Type 2 / Q000819:agonists; D014065:Tonometry, Ocular; D014822:Vitreous Body
chemical_list: C092006:7-Ala-angiotensin (1-7); D057912:Angiotensin II Type 2 Receptor Blockers; D007093:Imidazoles; D009842:Oligopeptides; D010446:Peptide Fragments; D011725:Pyridines; D044139:Receptor, Angiotensin, Type 2; D000804:Angiotensin II; C060894:CGP 42112A; C073402:PD 123319; D000803:Angiotensin I; C118790:angiotensin I (1-7)